Načítá se...
Biochronomer™ technology and the development of APF530, a sustained release formulation of granisetron
Granisetron and other 5-hydroxytryptamine type 3 (5-HT(3)) receptor antagonists are first-line agents for preventing chemotherapy-induced nausea and vomiting (CINV). Current treatment guidelines prefer the longer-acting agent, palonosetron, for CINV prevention in some chemotherapy regimens. A new gr...
Uloženo v:
| Vydáno v: | J Exp Pharmacol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4863535/ https://ncbi.nlm.nih.gov/pubmed/27186139 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JEP.S68880 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|